As many companies continue to struggle in the face of the coronavirus (“COVID-19”) pandemic, some of them can add increased regulatory scrutiny to their list of stressors. Over the last couple of months, the United States Federal Trade Commission and the Food and Drug Administration have issued over 100 warning letters to companies making allegedly






